Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Pharmstandard Falls First Day in 5 on Buyback Woes: Moscow Mover

Don't Miss Out —
Follow us on:

June 13 (Bloomberg) -- OAO Pharmstandard snapped four days of gains on concern minority shareholders won’t be able to participate in a share buyback of Russia’s largest drugmaker.

The stock dropped 1.5 percent to 1,401.10 rubles as of 12:09 p.m. in Moscow. Markets were closed June 11-12 for public holidays.

Pharmstandard approved a possible purchase of as much as 1.1 billion rubles ($33.7 million) of ordinary shares by its subsidiary OAO Pharmstandard-Leksredstva during the next 12 months, according to an e-mailed statement June 9.

“It’s unclear who will benefit from this buyback,” Tigran Hovhannisyan, an analyst at Uralsib Capital in Moscow, said by phone. “Most likely, this is a hidden dividend for the majority shareholder.”

The purchased shares may be used in merger and acquisition deals, according to the statement. The company’s shareholders decided not to pay 2011 dividends on May 25. Augment Investments Ltd. owns 54 percent of the company, Bloomberg data show.

To contact the reporter on this story: Ksenia Galouchko in Moscow at kgalouchko1@bloomberg.net;

To contact the editor responsible for this story: Gavin Serkin at gserkin@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.